Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00895895 · ClinicalTrials.gov registry record · Phase 2
Study Comparing 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer Disease
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 526
- Enrollment target
NCT00895895 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 526 participants.
The verdict
NCT00895895, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 526 participants
- Enrollment target
Study Summary
The study will evaluate the efficacy and safety of an investigational drug called SAM-531 at three dosage levels. Subjects will receive either one of the 3 dosage levels of SAM-531, donepezil or placebo for the first 24 weeks of the study (period I). Subjects who receive placebo for period I will be assigned to receive the highest dose of SAM-531 SAM-531 for the remaining 28 weeks of the study, while subjects who received one of the three SAM-531 dosage levels or donepezil in period I will continue with the same study drug (period II).
Interventions
- DRUG Placebo
- DRUG Donepezil
- DRUG SAM-531 1.5 mg
- DRUG SAM-531 3.0 mg
- DRUG SAM-531 5.0 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 526 participants |
| Start Date | 2009-05 |
| Est. Completion | 2011-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00895895
The ClinicalTrials.gov registry entry for NCT00895895 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 526 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT00895895 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00895895 about?
NCT00895895 is a clinical study titled "Study Comparing 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer Disease". The study will evaluate the efficacy and safety of an investigational drug called SAM-531 at three dosage levels. Subjects will receive either one of the 3 dosage levels of SAM-531, donepezil or placebo for the first 24 weeks of the study (period I). Subjects who receive placebo for period I will be...
What is the current status of trial NCT00895895?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 526 participants. The study started on 2009-05. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00895895?
The interventions under investigation include: Placebo (DRUG), Donepezil (DRUG), SAM-531 1.5 mg (DRUG), SAM-531 3.0 mg (DRUG), SAM-531 5.0 mg (DRUG).
Who is sponsoring clinical trial NCT00895895?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.